FDA actions

January 2012
Travel Medicine Advisor;Jan2012 Supplement, p2
The article reports on the activities of the U.S. Food and Drug Administration (FDA) such as the issuance a safety communication which states that fenofibrate may not decrease the risk of major cardiovascular events and the approval of zolpidem for treatment of insomnia.


Related Articles

  • FDA wants lower doses for sleeping aids. Newman, Elizabeth // McKnight's Long-Term Care News;Feb2013, Vol. 34 Issue 2, p22 

    The article informs that the manufacturers of sleeping pills with the ingredient called zolpidem are being forced by the U.S. Food and Drug Administration to reduce the current recommended dose of the medications.

  • FDA Lowers Ambien Dosages-Driving Can Be Impaired the Morning After.  // Texas Journal of Chiropractic;Jan/Feb2013, Vol. 28 Issue 1, p15 

    The article informs that the U.S. Food and Drug Administration has reduced the recommended sleep drug dosages containing zolpidem, Ambien and Ambien CR for women by five milligrams (mg) for immediate-release products and 6.25 mg for extended-release formulations to reduce morning drowsiness.

  • FDA actions.  // Infectious Disease Alert;Jan2012 Pharmacology Watch, p2 

    This section offers news briefs on actions taken by the U.S. Food and Drug Administration (FDA) including requiring further clinical study for the drug Tripilix and the issuance approval for the drug Zolpidem.

  • FDA actions.  // OB/GYN Clinical Alert;Jan2012 Pharmacology, p2 

    The article reports on the actions taken by the U.S. Food and Drug Administration (FDA) which includes issuing of a safety communication for drug fenofibrate due to its inefficacy in reducing the risk of cardiovascular diseases and approval of new formulation of the drug Zolpidem by Transcept...

  • With a Little Help From a Pill. Walsleben, Joyce // New York;6/9/2014, Vol. 47 Issue 13, p24 

    The article explains how to make the most of some quick-fix sleep aids. Topics discussed include the Rozerm which should be taken 30 minutes before bed according to the U.S. Food Drug and Administration (FDA), Ambien, the most common drug with zolpidem that lasts about 6 hours and Nyquil which...

  • FDA actions in brief.  // Formulary;Dec2005, Vol. 40 Issue 12, p426 

    The article reports on drugs approved by the U.S. Food and Administration (FDA). The FDA approved the injectable antibiotic ertapenem for the treatment of moderate-to-severe complicated foot infections. Also, a dosing regimen and label change for fenofibrate capsules was approved by the FDA. The...

  • LifeCycle Pharma Receives FDA Approval For Fenofibrate. Sheridan, Cormac // BioWorld International;8/15/2007, Vol. 12 Issue 33, p1 

    The article reports that LifeCycle Pharma A/S has gained approval from the U.S. Food & Drug Administration (FDA) for fenofibrate for the treatment of hyperlipidemia and hypertriglyceridemia. A $4 million milestone payment to LifeCycle Pharma has been triggered by the approval. LifeCycle CEO...

  • health wire.  // Consumer Reports on Health;Aug2007, Vol. 19 Issue 8, p2 

    The article offers news briefs related to health in the U.S. A new analysis has found that very high doses of polyphenols in the tea may harm the liver, kidneys and intestines. In April 2007, the Food and Drug Administration gave 13 manufacturers approval to sell copies of ambien or zolpidem....

  • FDA Requires Lower Dose for Certain Sleep Drugs.  // Neurology Reviews;Feb2013, Vol. 21 Issue 2, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) require manufacturers to lower the current recommended doses of sleep drugs containing Zolpidem. It mentions that the high levels of Zolpidem drug in some patients causes impair activities that require alertness. It states that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics